Opus Genetics, Inc
Opus Genetics, Inc
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, autosomal recessive bestrophinopathy, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorder, vitelliform macular dystrophy, vitelliform macular dystrophy 2 | Recruiting | Phase 1 / Phase 2 | 2026-09-24 | NCT07185256 | |
| Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD) | Eye Diseases, Hereditary, Leber congenital amaurosis, eye disorder, retinal disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-15 | NCT07681778 | |
| Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients | Eye Diseases, Hereditary, Leber congenital amaurosis 5, eye disorder, retinal degeneration, retinal disorder | Recruiting | Phase 1 / Phase 2 | 2026-02-19 | NCT05616793 |